Digital Health
-
Cutting-Edge Client Base
At Wilson Sonsini, we focus on representing emerging and high-growth digital health companies that are transforming healthcare through technology, data, and AI-powered solutions.
-
Comprehensive Health Tech Experience
Our experience covers a broad spectrum of health tech, from telehealth and wellness apps to medical devices and AI-driven drug discovery.
-
Leading Advisor to Digital Health Innovators
Wilson Sonsini has more than 600 digital health clients, including 28 unicorns.
-
More than $30 Billion in Venture Financings
Since 2000, we’ve assisted U.S.-based digital health clients in raising more than $30 billion in aggregate seed and venture funding.
Wilson Sonsini represents digital health companies and their venture investors in nearly all areas of health tech, including telehealth and telemedicine, mobile health and wellness apps and platforms, healthcare data analytics, wearables, medical devices, wellness products, digital therapeutics, data/AI drug discovery, and precision medicine.
Our multidisciplinary team provides comprehensive support in all areas critical to digital health companies’ growth and success, including:
- Company formation
- Healthcare regulatory advising and corporate practice of medicine structuring
- FDA pre- and post-approval counseling
- Venture capital financings
- Commercial transactions
- AI development and utilization
- Patents, trademarks, and intellectual property protections
- HIPAA compliance and healthcare data privacy
- Litigation and enforcement
- Mergers & acquisitions
- Initial public offerings (IPOs)
With a focus on emerging companies, Wilson Sonsini has robust experience navigating legal risks associated with the use of the most cutting-edge technology in healthcare. These technologies often outpace the legislatures and courts tasked with regulating them, requiring advice that balances legal, ethical, and business needs. Our team offers creative solutions to compliance obstacles tailored to the company’s stage, size, and risk tolerance, with rapid turnaround times and cost-effective advising, including fixed-fee pricing options.
Overview
Wilson Sonsini represents digital health companies and their venture investors in nearly all areas of health tech, including telehealth and telemedicine, mobile health and wellness apps and platforms, healthcare data analytics, wearables, medical devices, wellness products, digital therapeutics, data/AI drug discovery, and precision medicine.
Our multidisciplinary team provides comprehensive support in all areas critical to digital health companies’ growth and success, including:
- Company formation
- Healthcare regulatory advising and corporate practice of medicine structuring
- FDA pre- and post-approval counseling
- Venture capital financings
- Commercial transactions
- AI development and utilization
- Patents, trademarks, and intellectual property protections
- HIPAA compliance and healthcare data privacy
- Litigation and enforcement
- Mergers & acquisitions
- Initial public offerings (IPOs)
With a focus on emerging companies, Wilson Sonsini has robust experience navigating legal risks associated with the use of the most cutting-edge technology in healthcare. These technologies often outpace the legislatures and courts tasked with regulating them, requiring advice that balances legal, ethical, and business needs. Our team offers creative solutions to compliance obstacles tailored to the company’s stage, size, and risk tolerance, with rapid turnaround times and cost-effective advising, including fixed-fee pricing options.
Newsletters
2026 Mid-Year Technology and Life Sciences PIPE and RDO Report
Wilson Sonsini is pleased to present the 2026 Mid-Year Technology and Life Sciences PIPE and RDO Report, analyzing 103 private investments in public equity (PIPEs) and registered direct offerings (RDOs) by U.S.-based technology and life sciences companies between January 1 and June 30, 2026.
Client Advisories
Evolving Expectations for AI in Mental Health
Artificial intelligence (AI)-enabled mental health products are becoming more ubiquitous with many individuals turning to chatbots, digital companions, coaching tools, and other AI systems for mental health support. They are also attracting increased attention from regulators, policymakers, and courts. As discussed in our previous client alert, Legal Framework for AI in Mental Healthcare, these products already fall within a patchwork of federal and state regulatory frameworks. Recent developments suggest government scrutiny of the sector is likely to continue increasing, including recent actions by agencies, state laws, and emerging litigation. For companies developing AI-enabled mental health products, key considerations may include medical device regulation, emerging state AI laws, Federal Trade Commission (FTC) oversight of health-related claims, privacy, transparency and health data use, and potential liability theories, including the unauthorized practice of medicine or psychology.
Client Highlights
Wilson Sonsini Advises Scan.com on $220 Million Combined Equity and Debt Financing
On August 31, 2026, Scan.com, a digital medical imaging and radiology booking platform that connects patients, doctors, and diagnostic imaging centers in the U.S. and the UK, announced it has closed $220 million in combined equity and debt financing. The $90 million equity round was led by Noteus Partners, with participation from Aviva, Concord Health Partners, YZR Capital, Oxford Capital, and others. $130 million of debt facilities supporting mergers and acquisitions and working capital were provided by VerisFi Capital and Atempo Growth. Wilson Sonsini Goodrich & Rosati advised Scan.com on the transaction.
Alerts
CMS Proposes Changes to Incentivize FHIR-enabled Electronic Prior Authorization Use
On July 14, 2026, the Centers for Medicare & Medicaid Services (CMS) announced the CY 2027 Physician Fee Schedule (PFS) proposed rule. The proposed rule includes modifications to further incentivize the use of electronic prior authorization in Medicare Ambulatory Specialty Models (ASMs) and the Merit-based Incentive Payment System (MIPS) by health care providers. This builds on prior CMS regulations related to prior authorization which imposed requirements on certain health plans, but not on health care providers (see 2024 CMS Interoperability and Prior Authorization final rule). These changes are not “PFS” in the technical sense of altering relative value unit (RVU) or conversion-factor payment calculations, but rather are Quality Payment Program (QPP) and Center for Medicare and Medicaid Innovation (CMMI) policy changes that are included in the same omnibus annual rulemaking package. For CMS’s proposed PFS and Hospital Outpatient Prospective Payment System (OPPS) payment changes, see our previous client alert, “Health Reimbursement Signals: CMS Proposes Payment Frameworks for ‘Software as a Medical Service.’”1
Insights
Newsletters
2026 Mid-Year Technology and Life Sciences PIPE and RDO Report
Wilson Sonsini is pleased to present the 2026 Mid-Year Technology and Life Sciences PIPE and RDO Report, analyzing 103 private investments in public equity (PIPEs) and registered direct offerings (RDOs) by U.S.-based technology and life sciences companies between January 1 and June 30, 2026.
Client Advisories
Evolving Expectations for AI in Mental Health
Artificial intelligence (AI)-enabled mental health products are becoming more ubiquitous with many individuals turning to chatbots, digital companions, coaching tools, and other AI systems for mental health support. They are also attracting increased attention from regulators, policymakers, and courts. As discussed in our previous client alert, Legal Framework for AI in Mental Healthcare, these products already fall within a patchwork of federal and state regulatory frameworks. Recent developments suggest government scrutiny of the sector is likely to continue increasing, including recent actions by agencies, state laws, and emerging litigation. For companies developing AI-enabled mental health products, key considerations may include medical device regulation, emerging state AI laws, Federal Trade Commission (FTC) oversight of health-related claims, privacy, transparency and health data use, and potential liability theories, including the unauthorized practice of medicine or psychology.
Client Highlights
Wilson Sonsini Advises Scan.com on $220 Million Combined Equity and Debt Financing
On August 31, 2026, Scan.com, a digital medical imaging and radiology booking platform that connects patients, doctors, and diagnostic imaging centers in the U.S. and the UK, announced it has closed $220 million in combined equity and debt financing. The $90 million equity round was led by Noteus Partners, with participation from Aviva, Concord Health Partners, YZR Capital, Oxford Capital, and others. $130 million of debt facilities supporting mergers and acquisitions and working capital were provided by VerisFi Capital and Atempo Growth. Wilson Sonsini Goodrich & Rosati advised Scan.com on the transaction.
Alerts
CMS Proposes Changes to Incentivize FHIR-enabled Electronic Prior Authorization Use
On July 14, 2026, the Centers for Medicare & Medicaid Services (CMS) announced the CY 2027 Physician Fee Schedule (PFS) proposed rule. The proposed rule includes modifications to further incentivize the use of electronic prior authorization in Medicare Ambulatory Specialty Models (ASMs) and the Merit-based Incentive Payment System (MIPS) by health care providers. This builds on prior CMS regulations related to prior authorization which imposed requirements on certain health plans, but not on health care providers (see 2024 CMS Interoperability and Prior Authorization final rule). These changes are not “PFS” in the technical sense of altering relative value unit (RVU) or conversion-factor payment calculations, but rather are Quality Payment Program (QPP) and Center for Medicare and Medicaid Innovation (CMMI) policy changes that are included in the same omnibus annual rulemaking package. For CMS’s proposed PFS and Hospital Outpatient Prospective Payment System (OPPS) payment changes, see our previous client alert, “Health Reimbursement Signals: CMS Proposes Payment Frameworks for ‘Software as a Medical Service.’”1
Affiliated Programs
DHNY Summit 2026
Wilson Sonsini is a proud sponsor of DHNY. As AI moves into clinical care, the rules governing its use are still taking shape. Wilson Sonsini knows it's important to bring together founders, agency leaders, and regulatory advisors to explore the policy questions shaping AI in healthcare.
Speaking Engagements
Data and Situational Awareness for Medical and Public Health Preparedness and Response Workshop Series
Wilson Sonsini partner Jodi Daniel is participating the "Data Systems, Reliability, and Governance" webinar on July 21, 2026, as part of a workshop series convened by the National Academies' Forum on Medical and Public Health Preparedness for Disasters and Emergencies. Jodi joins fellow panelists representing consulting and healthcare data industries for the session "Governing and Sharing Data." Panelists will examine governance structures, legal frameworks, and policies that influence data access, sharing, and use during disasters and emergencies. They will also explore challenges and opportunities related to privacy, security, interoperability, and cross-sector information sharing.
WSGR Events
Navigating the Corporate Practice of Medicine: Compliance Essentials and Recent Developments
View the webinar recording here.
Affiliated Programs
The L Suite 2026 TechGC New York Digital Health Forum
Wilson Sonsini will sponsor The L Suite 2026 TechGC New York Digital Health Forum, a half-day event designed for general counsel and chief legal officers in the industry. Multiple content sessions will explore emerging legal challenges, including oversight of AI-enabled products, compliance obligations for data sharing, and expanding liability tied to model transparency and data provenance. Participants will discuss how evolving FDA, CMS, and DEA priorities are shaping both legal and business strategy.
WSGR Events
2026 Medical Device & Digital Health Conference
Wilson Sonsini’s 33rd Annual Medical Device & Digital Health Conference convenes industry leaders, investors, and innovators to explore the forces shaping medical device technology and digital health today. The program delivers valuable insights across innovation, regulation, capital markets, and commercialization, addressing topics of critical importance to companies navigating strategic growth and transformation.
Events
Affiliated Programs
DHNY Summit 2026
Wilson Sonsini is a proud sponsor of DHNY. As AI moves into clinical care, the rules governing its use are still taking shape. Wilson Sonsini knows it's important to bring together founders, agency leaders, and regulatory advisors to explore the policy questions shaping AI in healthcare.
Speaking Engagements
Data and Situational Awareness for Medical and Public Health Preparedness and Response Workshop Series
Wilson Sonsini partner Jodi Daniel is participating the "Data Systems, Reliability, and Governance" webinar on July 21, 2026, as part of a workshop series convened by the National Academies' Forum on Medical and Public Health Preparedness for Disasters and Emergencies. Jodi joins fellow panelists representing consulting and healthcare data industries for the session "Governing and Sharing Data." Panelists will examine governance structures, legal frameworks, and policies that influence data access, sharing, and use during disasters and emergencies. They will also explore challenges and opportunities related to privacy, security, interoperability, and cross-sector information sharing.
WSGR Events
Navigating the Corporate Practice of Medicine: Compliance Essentials and Recent Developments
View the webinar recording here.
Affiliated Programs
The L Suite 2026 TechGC New York Digital Health Forum
Wilson Sonsini will sponsor The L Suite 2026 TechGC New York Digital Health Forum, a half-day event designed for general counsel and chief legal officers in the industry. Multiple content sessions will explore emerging legal challenges, including oversight of AI-enabled products, compliance obligations for data sharing, and expanding liability tied to model transparency and data provenance. Participants will discuss how evolving FDA, CMS, and DEA priorities are shaping both legal and business strategy.
WSGR Events
2026 Medical Device & Digital Health Conference
Wilson Sonsini’s 33rd Annual Medical Device & Digital Health Conference convenes industry leaders, investors, and innovators to explore the forces shaping medical device technology and digital health today. The program delivers valuable insights across innovation, regulation, capital markets, and commercialization, addressing topics of critical importance to companies navigating strategic growth and transformation.
Jodi Daniel
Partner
Jodi Daniel is a nationally recognized leader in digital health law and policy, trusted by health care organizations and technology innovators to navigate the complex and dynamic regulatory landscape of digital health and wellness. With over 30 years of experience in healthcare innovation—including 15 years as a lawyer and senior policymaker at the U.S. Department of Health and Human Services (HHS)—Jodi leverages her extensive experience in digital health and health data to deliver strategic, practical advice to clients engaged in groundbreaking products and services that raise novel legal, policy, and ethical issues.
Andrea Linna
Partner
Andrea Linna is a partner at Wilson Sonsini Goodrich & Rosati, where she is a member of the firm’s digital health industry group and its healthcare practice. With more than 15 years dedicated to healthcare law, Andrea exclusively represents digital health and health tech clients, from emerging companies to established industry players and their venture capital investors.
Eva F. Yin
Partner
Eva Yin, Ph.D., M.P.H., is a partner in Wilson Sonsini Goodrich & Rosati’s FDA regulatory, healthcare, and consumer products practice. Her practice includes conducting FDA and healthcare regulatory due diligence for corporate transactions; providing legal counsel to manufacturers regarding FDA approval/clearance for various products—including medical devices, mobile apps, and drugs, FDA compliance, regulation of promotional materials and labeling, and manufacturer compliance under federal and state healthcare laws, e.g., the federal Anti-Kickback Statute (AKS), False Claims Act (FCA), Sunshine Act, state licensing laws, corporate practice of medicine, etc.; reviewing contracts and compliance policies for manufacturers; and providing legal analysis and risk assessment of business models and fee arrangements involving patient assistance programs, healthcare professionals, or hospitals/clinics under federal and state healthcare laws and regulations.
Lang Liu
Partner
Lang represents public and private companies, investment banks and venture capital firms.
Megan J. Baier
Chief Executive Officer of Wilson Sonsini
Megan Baier is chief executive officer of Wilson Sonsini and a member of the firm’s board of directors. As CEO, she is responsible for firm strategy, culture, and talent, and leads the day-to-day management of the firm’s business performance, including its operations, financial results, growth, AI and innovation, and risk management.
Megan has spent her career advising founders, boards, and public companies through the moments that define them: first financings, public offerings, and the governance decisions that follow. As a member of Wilson Sonsini's New York corporate group, she combines deep technical command of securities law with the judgment and steadiness clients need when the stakes are high.
Megan has spent her career advising founders, boards, and public companies through the moments that define them: first financings, public offerings, and the governance decisions that follow. As a member of Wilson Sonsini's New York corporate group, she combines deep technical command of securities law with the judgment and steadiness clients need when the stakes are high.
Mark B. Baudler
Partner
Mark is a corporate law veteran, having advised start-ups and mature public companies for more than 25 years.
Farah B. Gerdes
Partner
Farah focuses on the representation of pharmaceutical, biotechnology, medical device, and diagnostic companies in complex collaboration and partnering transactions.
Ali R. Alemozafar
Partner
Ali counsels clients on patent strategy, prosecution, and diligence for financings, M&A, and IPOs.
Salil Gandhi
Partner
Salil Gandhi is a partner in the New York office of Wilson Sonsini Goodrich & Rosati and a co-leader of the firm’s emerging companies practice. Salil focuses on corporate and securities law and specializes in the representation of emerging growth companies throughout their lifecycles, particularly in the life sciences and technology sectors. He also counsels venture capital funds and other private equity funds on structuring and executing investment transactions ranging from angel to control investments, as well as portfolio dispositions.
People
Jodi Daniel
Partner
Jodi Daniel is a nationally recognized leader in digital health law and policy, trusted by health care organizations and technology innovators to navigate the complex and dynamic regulatory landscape of digital health and wellness. With over 30 years of experience in healthcare innovation—including 15 years as a lawyer and senior policymaker at the U.S. Department of Health and Human Services (HHS)—Jodi leverages her extensive experience in digital health and health data to deliver strategic, practical advice to clients engaged in groundbreaking products and services that raise novel legal, policy, and ethical issues.
Andrea Linna
Partner
Andrea Linna is a partner at Wilson Sonsini Goodrich & Rosati, where she is a member of the firm’s digital health industry group and its healthcare practice. With more than 15 years dedicated to healthcare law, Andrea exclusively represents digital health and health tech clients, from emerging companies to established industry players and their venture capital investors.
Eva F. Yin
Partner
Eva Yin, Ph.D., M.P.H., is a partner in Wilson Sonsini Goodrich & Rosati’s FDA regulatory, healthcare, and consumer products practice. Her practice includes conducting FDA and healthcare regulatory due diligence for corporate transactions; providing legal counsel to manufacturers regarding FDA approval/clearance for various products—including medical devices, mobile apps, and drugs, FDA compliance, regulation of promotional materials and labeling, and manufacturer compliance under federal and state healthcare laws, e.g., the federal Anti-Kickback Statute (AKS), False Claims Act (FCA), Sunshine Act, state licensing laws, corporate practice of medicine, etc.; reviewing contracts and compliance policies for manufacturers; and providing legal analysis and risk assessment of business models and fee arrangements involving patient assistance programs, healthcare professionals, or hospitals/clinics under federal and state healthcare laws and regulations.
Lang Liu
Partner
Lang represents public and private companies, investment banks and venture capital firms.
Megan J. Baier
Chief Executive Officer of Wilson Sonsini
Megan Baier is chief executive officer of Wilson Sonsini and a member of the firm’s board of directors. As CEO, she is responsible for firm strategy, culture, and talent, and leads the day-to-day management of the firm’s business performance, including its operations, financial results, growth, AI and innovation, and risk management.
Megan has spent her career advising founders, boards, and public companies through the moments that define them: first financings, public offerings, and the governance decisions that follow. As a member of Wilson Sonsini's New York corporate group, she combines deep technical command of securities law with the judgment and steadiness clients need when the stakes are high.
Megan has spent her career advising founders, boards, and public companies through the moments that define them: first financings, public offerings, and the governance decisions that follow. As a member of Wilson Sonsini's New York corporate group, she combines deep technical command of securities law with the judgment and steadiness clients need when the stakes are high.
Mark B. Baudler
Partner
Mark is a corporate law veteran, having advised start-ups and mature public companies for more than 25 years.
Farah B. Gerdes
Partner
Farah focuses on the representation of pharmaceutical, biotechnology, medical device, and diagnostic companies in complex collaboration and partnering transactions.
Ali R. Alemozafar
Partner
Ali counsels clients on patent strategy, prosecution, and diligence for financings, M&A, and IPOs.
Salil Gandhi
Partner
Salil Gandhi is a partner in the New York office of Wilson Sonsini Goodrich & Rosati and a co-leader of the firm’s emerging companies practice. Salil focuses on corporate and securities law and specializes in the representation of emerging growth companies throughout their lifecycles, particularly in the life sciences and technology sectors. He also counsels venture capital funds and other private equity funds on structuring and executing investment transactions ranging from angel to control investments, as well as portfolio dispositions.
WSGR On-Demand Learning
- Webinar - Navigating the Corporate Practice of Medicine: Compliance Essentials and Recent Developments
- Digital Health Webinar Series - Session 1: Navigating the Legal Complexities of Digital Healthcare Regulations
- Digital Health Webinar Series - Session 2: Corporate Practice of Medicine
- Digital Health Webinar Series - Session 3: Value Based Care
- Digital Health Webinar Series - Session 4: Interoperability and Information Blocking Regulations
- Digital Health Webinar Series - Session 5: Marketing and Advertising for Digital Health Companies
- Digital Health Webinar Series - Session 6: AI in the Digital Health Industry: Key Regulatory, IP, and Commercial Topics
- Digital Health Webinar Series - Session 7: Privacy & Artificial Intelligence
Credit for online viewing with checkpoints is available in California (participatory), New York (experienced attorneys only), and Texas (accredited). For questions regarding any other states, please contact Wilson Sonsini’s MCLE Manager. Please note that you may be prompted to create an account the first time you access the site.
Webinars
WSGR On-Demand Learning
- Webinar - Navigating the Corporate Practice of Medicine: Compliance Essentials and Recent Developments
- Digital Health Webinar Series - Session 1: Navigating the Legal Complexities of Digital Healthcare Regulations
- Digital Health Webinar Series - Session 2: Corporate Practice of Medicine
- Digital Health Webinar Series - Session 3: Value Based Care
- Digital Health Webinar Series - Session 4: Interoperability and Information Blocking Regulations
- Digital Health Webinar Series - Session 5: Marketing and Advertising for Digital Health Companies
- Digital Health Webinar Series - Session 6: AI in the Digital Health Industry: Key Regulatory, IP, and Commercial Topics
- Digital Health Webinar Series - Session 7: Privacy & Artificial Intelligence
Credit for online viewing with checkpoints is available in California (participatory), New York (experienced attorneys only), and Texas (accredited). For questions regarding any other states, please contact Wilson Sonsini’s MCLE Manager. Please note that you may be prompted to create an account the first time you access the site.
Related Practices
- Capital Markets
- Corporate
- Corporate Governance
- Corporate Life Sciences
- Data, Privacy, and Cybersecurity
- Healthcare and FDA Regulatory
- Federal Trade Commission
- Government Investigations
- Internet Strategy and Litigation
- Life Sciences Business Advisory Practice
- Mergers & Acquisitions
- Patents and Innovations
- Public Company Representation
- Regulatory
- Technology Transactions
- Trademark and Advertising
- U.S. Expansion
Recent Insights
Newsletters
2026 Mid-Year Technology and Life Sciences PIPE and RDO Report
Wilson Sonsini is pleased to present the 2026 Mid-Year Technology and Life Sciences PIPE and RDO Report, analyzing 103 private investments in public equity (PIPEs) and registered direct offerings (RDOs) by U.S.-based technology and life sciences companies between January 1 and June 30, 2026.
Learn More
Client Advisories
Evolving Expectations for AI in Mental Health
Artificial intelligence (AI)-enabled mental health products are becoming more ubiquitous with many individuals turning to chatbots, digital companions, coaching tools, and other AI systems for mental health support. They are also attracting increased attention from regulators, policymakers, and courts. As discussed in our previous client alert, Legal Framework for AI in Mental Healthcare, these products already fall within a patchwork of federal and state regulatory frameworks. Recent developments suggest government scrutiny of the sector is likely to continue increasing, including recent actions by agencies, state laws, and emerging litigation. For companies developing AI-enabled mental health products, key considerations may include medical device regulation, emerging state AI laws, Federal Trade Commission (FTC) oversight of health-related claims, privacy, transparency and health data use, and potential liability theories, including the unauthorized practice of medicine or psychology.
Learn More
Recent Events
Affiliated Programs
DHNY Summit 2026
Wilson Sonsini is a proud sponsor of DHNY. As AI moves into clinical care, the rules governing its use are still taking shape. Wilson Sonsini knows it's important to bring together founders, agency leaders, and regulatory advisors to explore the policy questions shaping AI in healthcare.
Learn More
Speaking Engagements
Data and Situational Awareness for Medical and Public Health Preparedness and Response Workshop Series
Wilson Sonsini partner Jodi Daniel is participating the "Data Systems, Reliability, and Governance" webinar on July 21, 2026, as part of a workshop series convened by the National Academies' Forum on Medical and Public Health Preparedness for Disasters and Emergencies. Jodi joins fellow panelists representing consulting and healthcare data industries for the session "Governing and Sharing Data." Panelists will examine governance structures, legal frameworks, and policies that influence data access, sharing, and use during disasters and emergencies. They will also explore challenges and opportunities related to privacy, security, interoperability, and cross-sector information sharing.
Learn More
- Privacy Policy
- Terms of Use
- Accessibility
Copyright © 2026 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.